Intellia Therapeutics Obtains $15,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=18c573e0-1eec-4918-9e05-59ff0bcd38f2 - Date
11/19/2014 - Company Name
Intellia Therapeutics - Mailing Address
130 Brookline Street Cambridge, MA 02139 USA - Company Description
Intellia Therapeutic’s core mission is to lead the industry in therapeutic gene editing, utilizing the promise of the CRISPR/Cas9 technology. We are solely focused on the research and clinical development of gene editing therapies for patients with genetically-based diseases. - Website
http://www.intelliatx.com - Transaction Type
Venture Equity - Transaction Amount
$15,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
- Venture Investor
